Introduction: The CTD Format for Generic ANDA and ANDS Submissions plays a fundamental role in the successful approval of generic […]
What Is the Role of the CTD Format in Generic ANDA and ANDS? Read More »
Peptide CDMO Selection Canadian vs. US Peptide CDMOs: Which Is Right for Your Program? By Anusha Sinha • July 22,
Canadian vs. US Peptide CDMOs: Which Is Right for Your Program? Read More »
Peptide Manufacturing Strategy Peptide CDMO vs. CMO: Which Does Your Program Actually Need? By Anusha Sinha • July 22, 2026
Peptide CDMO vs. CMO: Which Does Your Program Actually Need? Read More »
Introduction Choosing a peptide Contract Development and Manufacturing Organization (CDMO) in the US requires a comprehensive assessment of technical synthesis
How to Choose a Peptide CDMO in the US: A Buyer’s Checklist Read More »
Introduction: Sponsors developing a drug for the North American market almost always end up filing in both the United States
Introduction Establishing structural equivalence through a specialized Disulfide Bond Mapping Service for Biosimilars is critical for verifying higher-order structural integrity,
Introduction Peptide API Scale-Up requires translating laboratory solid-phase synthesis into scalable, robust, and compliant current Good Manufacturing Practice (cGMP) processes
Peptide API Scale-Up: From Milligram Discovery Batches to Kilogram GMP Production Read More »
Introduction The immunogenicity of peptide-oligonucleotide conjugates is a multifaceted biological phenomenon resulting from the synergistic interplay of immunogenic peptide epitopes,
Introduction: Elemental Impurities and Residual Solvents Testing for Synthetic Peptide APIs has become one of the more scrutinized areas of
Peptide Formulation & Stability Peptide Drug Formulation Challenges: Lyophilization, Prefilled Syringes, and Injectable Stability By Anusha Sinha • July 20,
